Litcius/Paper detail

P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions

Tobias Derfuß, Martin S. Weber, Richard A. Hughes, J. Eggebrecht, Q. Wang, Annette Sauter, Harold Koendgen, Stephen L. Hauser, Amit Bar‐Or, Hans‐Peter Hartung

2020Clinical Neurophysiology27 citationsDOIOpen Access PDF

Topics & Concepts

OcrelizumabOpen labelMultiple sclerosisMedicineAntibodyOpen label studyImmunologyClinical trialInternal medicineAdverse effectRituximabImmunodeficiency and Autoimmune DisordersBiosimilars and Bioanalytical MethodsSARS-CoV-2 and COVID-19 Research
P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions | Litcius